— Low dose (12.5mg/day) of controlled release paroxetine, known as Paxil CR, was significantly superior to placebo in treating depression, according to data presented this week at the National Institute of Mental Health’s (NIMH) annual National Clinical Drug Evaluation Unit (NCDEU) meeting.
This study showed that controlled release paroxetine is well tolerated with low patient drop out rates.
Additionally, in two separate pooled studies on controlled release paroxetine presented at the meeting subjects reported relief of depressed mood and anxiety symptoms after only one week of treatment and low rates of nausea, one of the most common side effects that cause people to stop taking antidepressant medication.
“Often times, antidepressant treatment fails because patients find the side effects unacceptable, and if they refuse to take their medication they aren’t going to have a good chance of getting better,” said Robert N. Golden, M.D., lead investigator and professor and chair, Department of Psychiatry, University of North Carolina School of Medicine.
“These data demonstrate that controlled release paroxetine has a favorable side effect profile without compromising the effectiveness of the medication.”
Controlled Release Paroxetine Shows Symptom Improvement as Early as Week One In two 12-week, randomized, double-blind, placebo-controlled, flexible dose (25mg-62.5mg) studies with 640 people diagnosed with major depression, controlled release paroxetine was found to be effective in improving depression and anxiety symptoms as early as the first week of treatment.
Also during week one, patients taking controlled release paroxetine experienced low rates of nausea.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!